From: Health policy and systems research agendas in developing countries
 | Beneficiaries or Issues |  |  | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Topic | Elderly | Children | Community | Primary | Hospital | Urban | Rural | Equity | Gender | Indigenous peoples/traditional medicine | Public private mix | TOTAL | ||||||||||||
 | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | A | B | n = | B |
Accessibility | Â | Â | 2 | 3 | 10 | 7 | 7 | 7 | 10 | 8 | 7 | 12 | 19 | 20 | 17 | 14 | 19 | 17 | 2 | 11 | 7 | 7 | 42 | 10 |
Community participation | 9 | 20 | 4 | 3 | 43 | 19 | 13 | 7 | Â | Â | 13 | 12 | 4 | 3 | Â | Â | 13 | 7 | Â | Â | Â | Â | 23 | 6 |
costing & cost effectiveness | Â | Â | 13 | 3 | 13 | 2 | Â | Â | 38 | 6 | 13 | 4 | 13 | 3 | 13 | 2 | Â | Â | Â | Â | Â | Â | 8 | 2 |
Decentralisation/local health systems | Â | Â | 13 | 5 | 27 | 7 | 7 | 2 | Â | Â | 13 | 8 | 27 | 10 | 7 | 2 | 7 | 2 | Â | Â | Â | Â | 15 | 4 |
Disease burden | 15 | 50 | 21 | 19 | 3 | 2 | 3 | 2 | 6 | 4 | 12 | 15 | 9 | 8 | 6 | 4 | 24 | 17 | 3 | 11 | Â | Â | 34 | 8 |
Economic policy and health | 14 | 10 | 43 | 8 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 14 | 2 | 29 | 4 | Â | Â | Â | Â | 7 | 2 |
Equity | 6 | 10 | Â | Â | 6 | 2 | Â | Â | Â | Â | Â | Â | Â | Â | 78 | 28 | Â | Â | 11 | 22 | Â | Â | 18 | 4 |
Financing | Â | Â | Â | Â | 39 | 17 | Â | Â | Â | Â | 4 | 4 | 9 | 5 | 39 | 18 | 4 | 2 | Â | Â | 4 | 2 | 23 | 6 |
Human resources | Â | Â | Â | Â | 29 | 9 | 35 | 15 | 6 | 2 | 6 | 4 | 18 | 8 | Â | Â | Â | Â | 6 | 11 | Â | Â | 17 | 4 |
Inform. Educ. & Communication | Â | Â | 21 | 8 | Â | Â | 7 | 2 | 7 | 2 | 14 | 8 | 14 | 5 | Â | Â | 36 | 11 | Â | Â | Â | Â | 14 | 3 |
Information systems | Â | Â | Â | Â | 25 | 4 | 38 | 7 | 13 | 2 | Â | Â | 13 | 3 | 13 | 2 | Â | Â | Â | Â | Â | Â | 8 | 2 |
Insurance | Â | Â | Â | Â | 44 | 13 | Â | Â | Â | Â | 13 | 8 | 19 | 8 | 13 | 4 | Â | Â | 6 | 11 | 6 | 2 | 16 | 4 |
Management & Organization | Â | Â | 2 | 3 | 9 | 7 | 9 | 10 | 49 | 48 | 2 | 4 | 11 | 13 | 2 | 2 | 4 | 4 | Â | Â | 13 | 14 | 47 | 12 |
Pharmaceutical policy & Mgmnt. | Â | Â | Â | Â | Â | Â | 17 | 5 | 33 | 8 | Â | Â | 8 | 3 | 25 | 6 | 8 | 2 | 8 | 11 | Â | Â | 12 | 3 |
Policy process | Â | Â | Â | Â | 50 | 6 | Â | Â | Â | Â | 17 | 4 | Â | Â | 33 | 4 | Â | Â | Â | Â | Â | Â | 6 | 1 |
Programme evaluation | 2 | 10 | 22 | 24 | 2 | 2 | 17 | 17 | 5 | 4 | 12 | 19 | 2 | 3 | 2 | 2 | 2 | 2 | Â | Â | 32 | 30 | 41 | 10 |
Quality | Â | Â | Â | Â | 7 | 2 | 20 | 7 | 47 | 15 | Â | Â | 7 | 3 | Â | Â | 13 | 4 | Â | Â | 7 | 2 | 15 | 4 |
Research to evidence | Â | Â | Â | Â | Â | Â | 33 | 2 | Â | Â | Â | Â | Â | Â | 33 | 2 | Â | Â | Â | Â | 33 | 2 | 3 | 1 |
Sector Analysis | Â | Â | 11 | 11 | Â | Â | 11 | 10 | Â | Â | Â | Â | 8 | 8 | 11 | 8 | 8 | 7 | 3 | 11 | 47 | 40 | 36 | 9 |
None | Â | Â | 26 | 14 | 5 | 2 | 11 | 5 | Â | Â | Â | Â | 5 | 3 | Â | Â | 47 | 20 | 5 | 11 | Â | 0 | 19 | 5 |
n | Â | 10 | Â | 37 | Â | 54 | Â | 41 | Â | 48 | Â | 26 | Â | 40 | Â | 50 | Â | 46 | Â | 9 | Â | 43 | 404 | 100 |
% | 2 | 100 | 9 | 100 | 13 | 100 | 10 | 100 | 12 | 100 | 6 | 100 | 10 | 100 | 12 | 100 | 11 | 100 | 2 | 100 | 11 | 100 | Â | Â |